Kirby McInerney LLP Notifies Dexcom Inc. (DXCM) Investors of Filing of Class Action and Encourages Investors to Contact the Company

On July 25, 2024, Dexcom announced its financial results for the second quarter of 2024 and lowered its revenue guidance for the full fiscal year 2024. The company attributed its results and lowered its guidance to the execution of “several key strategic initiatives” that “did not meet (their) high standards.” On this news, the price of DexCom stock fell $43.85, or approximately 40.7%, from $107.85 per share on July 25, 2024 to a closing price of $64.00 per share on July 26, 2024.

If you purchased or otherwise acquired Dexcom securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected] or by completing this CONTACT FORM to discuss your rights or interests with respect to these matters at no cost to you.

Kirby McInerney LLP is a New York plaintiffs’ law firm specializing in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities class action lawsuits have resulted in recoveries totaling billions of dollars. More information about the firm can be found on the Kirby McInerney LLP website.

This press release may be considered Attorney Advertising in some jurisdictions under applicable law and ethical rules.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20240917594717/en/

Dexcom shares were down $100,000 at the time of the news release. -1.64 % to 68.94US dollar on the Nasdaq stock exchange (September 17, 2024, 11:20 p.m.).

Diskutieren Sie über die entaltenen Werte